Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $52.33.

Several analysts have issued reports on the stock. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Finally, Scotiabank increased their price target on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st.

Insider Activity

In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This represents a 11.20 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $37,000. Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 363 shares in the last quarter. CWM LLC raised its holdings in Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at $146,000.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $52.89 on Friday. The business’s 50 day simple moving average is $46.62 and its 200-day simple moving average is $44.07. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of 4.66 and a beta of 0.75. Agios Pharmaceuticals has a 12 month low of $20.96 and a 12 month high of $62.58.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.